Jaguar Health Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Jaguar Health de 32.8% y 44.9% respectivamente, mientras que el BPA crecerá en un 114.9% al año.

Información clave

32.8%

Tasa de crecimiento de los beneficios

114.9%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	27.6%
Tasa de crecimiento de los ingresos	44.9%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	01 May 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 49%

May 24

Jaguar Health, Inc. (NASDAQ:JAGX) Shares Fly 55% But Investors Aren't Buying For Growth

Mar 29

Jaguar Health, Inc. (NASDAQ:JAGX) Not Doing Enough For Some Investors As Its Shares Slump 39%

Jan 22

Positive Sentiment Still Eludes Jaguar Health, Inc. (NASDAQ:JAGX) Following 32% Share Price Slump

Jun 10

Jaguar Health (NASDAQ:JAGX) Is Carrying A Fair Bit Of Debt

Jan 23

Jaguar Health rises 19% on orphan drug tag for congenital diarrheal disorder treatment

Oct 17

Jaguar Health sells crofelemer and lechlemer royalty rights for $4M upfront

Aug 25

Jaguar Health gets 180-day grace period to regain compliance with Nasdaq's listing rule

Aug 19

Jaguar Health plans for conditional marketing application in Europe for Crofelemer, initially for Long-Hauler COVID-19 patients

Jan 11

Jaguar Health leaps higher in new year

Jan 05

Jaguar Health inks second Mytesi royalties agreement for $6M

Dec 23

Does Jaguar Health (NASDAQ:JAGX) Have A Healthy Balance Sheet?

Dec 02

Jaguar Health's crofelemer development nears SPAC funding in Europe, shares +61%

Nov 30

Jaguar Health EPS misses by $0.10, misses on revenue

Nov 16

Jaguar Health receives positive Nasdaq listing determination

Oct 29

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:JAGX - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2025	23	-21	N/A	-7	1
12/31/2024	15	-26	N/A	-11	1
3/31/2024	10	-38	-30	-30	N/A
12/31/2023	10	-41	-33	-33	N/A
9/30/2023	11	-40	-33	-32	N/A
6/30/2023	11	-44	-34	-34	N/A
3/31/2023	11	-42	-37	-35	N/A
12/31/2022	12	-47	-35	-33	N/A
9/30/2022	11	-54	-37	-36	N/A
6/30/2022	8	-54	-38	-37	N/A
3/31/2022	6	-59	-36	-36	N/A
12/31/2021	4	-53	-35	-35	N/A
9/30/2021	5	-50	-30	-30	N/A
6/30/2021	7	-46	-24	-24	N/A
3/31/2021	10	-42	-18	-18	N/A
12/31/2020	9	-39	-15	-15	N/A
9/30/2020	8	-35	-14	-14	N/A
6/30/2020	7	-39	-20	-20	N/A
3/31/2020	5	-45	-21	-21	N/A
12/31/2019	6	-45	-20	-20	N/A
9/30/2019	6	-48	-22	-22	N/A
6/30/2019	6	-43	-16	-16	N/A
3/31/2019	5	-34	-17	-17	N/A
12/31/2018	4	-32	-23	-23	N/A
9/30/2018	4	-41	-23	-23	N/A
6/30/2018	4	-30	-23	-23	N/A
3/31/2018	4	-24	-19	-19	N/A
12/31/2017	4	-22	N/A	-10	N/A
9/30/2017	3	-5	N/A	-7	N/A
6/30/2017	2	-14	N/A	-17	N/A
3/31/2017	1	-17	N/A	-15	N/A
12/31/2016	0	-15	N/A	-14	N/A
12/31/2015	0	5	N/A	1	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que JAGX siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que JAGX siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que JAGX siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (44.9% al año) de JAGX crezcan más rápidamente que los del mercado US (8.7% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (44.9% al año) de JAGX crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de JAGX se prevé que sea elevada dentro de 3 años.

Jaguar Health Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target decreased to US$4.00

Recent updates

Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 49%

Jaguar Health Announces 1-For-60 Reverse Stock Split in Order to Support Compliance with Nasdaq's Listing Standards

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Jaguar Health, Inc., Annual General Meeting, Jun 21, 2024

Jaguar Health, Inc. to Report Q1, 2024 Results on May 14, 2024

Jaguar Health, Inc. Establishes New Investigational New Animal Drug File with the Center for Veterinary Medicine of the U.S. Food and Drug Administration

Jaguar Health Receives Extension Until August 13, 2024, to Regain Compliance with Nasdaq's Bid Price Requirement

Jaguar Health, Inc. Appoints Massimo Radaelli, PhD, as President of Jaguar International

Full year 2023 earnings released: US$1.79 loss per share (vs US$36.18 loss in FY 2022)

Jaguar Health, Inc. (NASDAQ:JAGX) Shares Fly 55% But Investors Aren't Buying For Growth

Jaguar Health, Inc. to Report Q4, 2023 Results on Apr 01, 2024

Jaguar Health Receives Notification Letter from The Nasdaq Stock Market LLC

Jaguar Health, Inc. Announces FDA Agrees with Clinical Trial Protocol for Full Approval of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

Jaguar Health, Inc. (NASDAQ:JAGX) Not Doing Enough For Some Investors As Its Shares Slump 39%

Napo Pharmaceuticals, Inc. Announces Majority of Subjects in Placebo-Controlled Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy Chose to Continue on to Continue on to Stage II

FDA Approves Renewal of Canalevia-CA1, Jaguar Health’s Drug for Chemotherapy-Induced Diarrhea in Dogs

Jaguar Health, Inc. announced that it has received $0.06 million in funding

New major risk - Revenue and earnings growth

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Jaguar Health Receives Additional 180-Day Grace Period to Regain Compliance with Nasdaq's Bid Price Rule

Jaguar Health, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Jaguar Health, Inc. Announces Issuance of New US Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)

New major risk - Share price stability

New major risk - Financial position

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Jaguar Health Announces FDA Activation of Third-Party Investigational New Drug Application for Evaluation of Crofelemer for Treatment of Uncontrolled Diarrhea in Patient with Short Bowel Syndrome

Napo Pharmaceuticals Submits Investigational New Drug Application to FDA for MicroVillus Inclusion Disease

New major risk - Market cap size

Positive Sentiment Still Eludes Jaguar Health, Inc. (NASDAQ:JAGX) Following 32% Share Price Slump

Jaguar Health, Inc., Annual General Meeting, Jul 07, 2023

Jaguar Health, Inc. Appoints Stacey Tinianov to Scientific Advisory Board

First quarter 2023 earnings released: US$2.39 loss per share (vs US$30.17 loss in 1Q 2022)

Jaguar Health Receives Non-Compliance Notice from Nasdaq Regarding Minimum Bid Price Requirement

Jaguar Health, Inc. to Report Q1, 2023 Results on May 15, 2023

Jaguar Health, Inc. announced that it has received $1.86 million in funding

Jaguar Health, Inc. announced that it expects to receive $1.86 million in funding

Full year 2022 earnings: Revenues in line with analyst expectations

Jaguar Health Regains Compliance with Nasdaq’s Bid Price Requirement

Jaguar Health, Inc. Provides Updates Regarding its Focus on Rare and Orphan Disease Indications in the U.S. & Europe

Jaguar Health (NASDAQ:JAGX) Is Carrying A Fair Bit Of Debt

Jaguar Health, Inc. and Napo Pharmaceuticals Appoints Sandra M. Swain to the Scientific Advisory Board

Price target decreased to US$4.00

Jaguar Health Announces Publication in Breast Cancer Research and Treatment of Investigator-Initiated Phase 2 HALT-D Study of Crofelemer for Prevention of Chemotherapy-Induced Diarrhea (Cid) in Breast Cancer Patients

European Medicines Agency Grants Orphan Drug Designation for Crofelemer for Microvillus Inclusion Disease

Jaguar Health rises 19% on orphan drug tag for congenital diarrheal disorder treatment

Jaguar Health sells crofelemer and lechlemer royalty rights for $4M upfront

Jaguar Health Receives Additional 180-Day Grace Period to Regain Compliance with Nasdaq's Bid Price Rule

Jaguar Health gets 180-day grace period to regain compliance with Nasdaq's listing rule

Jaguar Health, Inc. announced delayed 10-Q filing

Jaguar Health rises on U.S. patent for treating chemotherapy-induced diarrhea

Jaguar Health, Inc. Appoints Anula Jayasuriya to Board of Directors and Forms Business Development Advisory Committee

Jaguar stock rises on license deal with SynWorld for Canalevia in China

Jaguar Health, Inc. Announces Appointment of Pravin Chaturvedi as Chief Scientific Officer and Chair of the Scientific Advisory Board

Jaguar Health CEO Lisa Conte - From Rainforest To Laboratory

Jaguar Health Regains Compliance with Nasdaq Bid Price Requirement

Jaguar Health shares jumps 13% after pricing $15M direct offering

Jaguar Health Explores Possibility of Conditional Marketing Authorization for Proposed Inflammatory Diarrhea Indication for Crofelemer, Initially in ‘Long-Hauler’ Covid-19 Recovery Patients in Europe

Jaguar Health plans for conditional marketing application in Europe for Crofelemer, initially for Long-Hauler COVID-19 patients

Jaguar Health leaps higher in new year

Jaguar Health inks second Mytesi royalties agreement for $6M

Jaguar Health Got Letter from Nasdaq Staying Stipulation for Company to Comply with Minimum Bid Price Requirement by Dec. 23

Does Jaguar Health (NASDAQ:JAGX) Have A Healthy Balance Sheet?

New 90-day high: US$0.46

Jaguar Health's crofelemer development nears SPAC funding in Europe, shares +61%

Jaguar Health, Inc. and Napo Pharmaceuticals, Inc. Plan to Study, Develop and Commercialize Crofelemer, the Company’s Novel Proprietary Drug, for an Indication of Inflammatory Diarrhea, Initially in Europe

Earnings beat expectations, revenue disappoints

Third quarter 2020 earnings released: US$0.20 loss per share

Jaguar Health EPS misses by $0.10, misses on revenue

Jaguar Health Receives Positive Nasdaq Listing Determination

Jaguar Health receives positive Nasdaq listing determination

New 90-day low: US$0.27

Jaguar Health, Inc. Announces Appointment of Melissa Yeager, J.D. as Senior Vice President, Regulatory Affairs and Quality Assurance

New 90-day low: US$0.29

New 90-day low - US$0.39